{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:53:56Z","timestamp":1740164036628,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare","award":["HI22C0999","HI22C0999"],"award-info":[{"award-number":["HI22C0999","HI22C0999"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin\u2019s lymphoma, for which cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab(R\u2013CHOP) is one of the standard regimens. Given that R\u2013CHOP is highly emetogenic, chemotherapy-induced nausea and vomiting (CINV) prevention is clinically important. However, there is a paucity of studies focusing on these patients. This study aimed to ascertain the effectiveness of an oral fixed-dose combination of netupitant and palonosetron (NEPA) in preventing CINV in patients with DLBCL undergoing first-line R-CHOP chemotherapy. Seventy patients were enrolled in this single-center prospective non-comparative study conducted between November 2020 and May 2023 in South Korea. NEPA was administered 1\u00a0h prior to chemotherapy initiation on day 1. The primary endpoint of the study was the complete response rate (no emesis, and no rescue medication) during the acute, delayed, and overall phases, which were assessed over a period of 120\u00a0h post-chemotherapy. The complete response rates for NEPA were 90.0% [95% CI 80.5, 95.9] for the acute phase, 85.7% [95% CI 75.3, 92.9] for the delayed phase, and 84.3% [95% CI 73.6, 91.9] for the overall phase, with no-emesis rates (acute: 97.1% [95% CI 97.1, 99.7], delayed: 95.7% [95% CI 88.0, 99.1], overall: 92.9% [95% CI 84.1, 97.6]). NEPA was well tolerated with no severe treatment-emergent adverse events. NEPA exhibited substantial efficacy in mitigating CINV in DLBCL patients undergoing R\u2013CHOP chemotherapy, demonstrating high CR and no-emesis rates, and favorable safety profiles.<\/jats:p>","DOI":"10.1038\/s41598-024-62057-4","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T14:02:19Z","timestamp":1715868139000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of netupitant\/palonosetron in preventing nausea and vomiting in diffuse large B cell lymphoma patients undergoing R\u2013CHOP chemotherapy"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5908-2607","authenticated-orcid":false,"given":"Kunye","family":"Kwak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1462-0502","authenticated-orcid":false,"given":"Ka-Won","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"key":"62057_CR1","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.3324\/haematol.2016.148809","volume":"101","author":"AM Perry","year":"2016","unstructured":"Perry, A. M. et al. Non-Hodgkin lymphoma in the developing world: Review of 4539 cases from the International non-hodgkin lymphoma classification project. Haematologica 101, 1244\u20131250. https:\/\/doi.org\/10.3324\/haematol.2016.148809 (2016).","journal-title":"Haematologica"},{"key":"62057_CR2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1080\/10428194.2021.1975188","volume":"63","author":"G Kanas","year":"2022","unstructured":"Kanas, G. et al. Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: Population-level projections for 2020\u20132025. Leuk. Lymphoma 63, 54\u201363. https:\/\/doi.org\/10.1080\/10428194.2021.1975188 (2022).","journal-title":"Leuk. Lymphoma"},{"key":"62057_CR3","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.21357","volume":"66","author":"LR Teras","year":"2016","unstructured":"Teras, L. R. et al. 2016 US lymphoid malignancy statistics by world health organization subtypes. CA Cancer J. Clin. 66, 443\u2013459. https:\/\/doi.org\/10.3322\/caac.21357 (2016).","journal-title":"CA Cancer J. Clin."},{"key":"62057_CR4","first-page":"111","volume":"11","author":"XQ Li","year":"2012","unstructured":"Li, X. Q., Li, G. D., Gao, Z. F., Zhou, X. G. & Zhu, X. Z. Distribution pattern of lymphoma subtypes in China: A nationwide multicenter study of 10002 cases. J. Diagn. Concepts Pract. 11, 111\u2013115 (2012).","journal-title":"J. Diagn. Concepts Pract."},{"key":"62057_CR5","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.4143\/crt.2020.089","volume":"52","author":"JS Kim","year":"2020","unstructured":"Kim, J. S. et al. Increasing incidence of B-cell non-hodgkin lymphoma and occurrence of second primary malignancies in South Korea: 10-year follow-up using the Korean national health information database. Cancer Res. Treat. 52, 1262\u20131272. https:\/\/doi.org\/10.4143\/crt.2020.089 (2020).","journal-title":"Cancer Res. Treat."},{"key":"62057_CR6","doi-asserted-by":"publisher","first-page":"12106","DOI":"10.1182\/blood-2022-169045","volume":"140","author":"M Garg","year":"2022","unstructured":"Garg, M. et al. Diffuse large B-cell lymphoma (DLBCL): A structured literature review of the epidemiology, treatment guidelines, and real-world treatment patterns. Blood 140, 12106\u201312107. https:\/\/doi.org\/10.1182\/blood-2022-169045 (2022).","journal-title":"Blood"},{"key":"62057_CR7","unstructured":"NCCN (2023) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) B-Cell Lymphomas (Version 3. 2023). https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1480. Accessed 1 June 2023."},{"key":"62057_CR8","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/jco.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh, P. J. et al. Antiemetics: ASCO guideline update. J. Clin. Oncol. 38, 2782\u20132797. https:\/\/doi.org\/10.1200\/jco.20.01296 (2020).","journal-title":"J. Clin. Oncol."},{"key":"62057_CR9","unstructured":"NCCN (2023) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Antiemesis (Version 2.2023). https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=3&id=1415. Accessed 31 May 2023."},{"key":"62057_CR10","doi-asserted-by":"publisher","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","volume":"27","author":"F Roila","year":"2016","unstructured":"Roila, F. et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann. Oncol. 27, v119\u2013v133. https:\/\/doi.org\/10.1093\/annonc\/mdw270 (2016).","journal-title":"Ann. Oncol."},{"key":"62057_CR11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/0277-5379(83)90418-2","volume":"19","author":"A Coates","year":"1983","unstructured":"Coates, A. et al. On the receiving end\u2013patient perception of the side-effects of cancer chemotherapy. Eur. J. Cancer Clin. Oncol. 19, 203\u2013208. https:\/\/doi.org\/10.1016\/0277-5379(83)90418-2 (1983).","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"62057_CR12","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1200\/jco.2000.18.19.3409","volume":"18","author":"JP Ioannidis","year":"2000","unstructured":"Ioannidis, J. P., Hesketh, P. J. & Lau, J. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J. Clin. Oncol. 18, 3409\u20133422. https:\/\/doi.org\/10.1200\/jco.2000.18.19.3409 (2000).","journal-title":"J. Clin. Oncol."},{"key":"62057_CR13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10147-017-1173-3","volume":"23","author":"T Takahashi","year":"2018","unstructured":"Takahashi, T. et al. A prospective study of palonosetron for prevention of chemotherapy-induced nausea and vomiting in malignant lymphoma patients following highly emetogenic chemotherapy. Int. J. Clin. Oncol. 23, 189\u2013194. https:\/\/doi.org\/10.1007\/s10147-017-1173-3 (2018).","journal-title":"Int. J. Clin. Oncol."},{"key":"62057_CR14","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1056\/nejm200005253422102","volume":"342","author":"Italian Group for Antiemetic Research","year":"2000","unstructured":"Italian Group for Antiemetic Research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N. Engl. J. Med. 342, 1554\u20131559. https:\/\/doi.org\/10.1056\/nejm200005253422102 (2000).","journal-title":"N. Engl. J. Med."},{"key":"62057_CR15","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.currproblcancer.2017.09.001","volume":"41","author":"M Morita","year":"2017","unstructured":"Morita, M. et al. Efficacy of aprepitant for CHOP chemotherapy-induced nausea, vomiting, and anorexia. Curr. Probl. Cancer 41, 419\u2013425. https:\/\/doi.org\/10.1016\/j.currproblcancer.2017.09.001 (2017).","journal-title":"Curr. Probl. Cancer"},{"key":"62057_CR16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1445-5994.2011.02637.x","volume":"43","author":"HF Gao","year":"2013","unstructured":"Gao, H. F., Liang, Y., Zhou, N. N., Zhang, D. S. & Wu, H. Y. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy. Intern. Med. J. 43, 73\u201376. https:\/\/doi.org\/10.1111\/j.1445-5994.2011.02637.x (2013).","journal-title":"Intern. Med. J."},{"key":"62057_CR17","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/j.ejca.2008.11.046","volume":"45","author":"K Jordan","year":"2009","unstructured":"Jordan, K. et al. Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. Eur. J. Cancer 45, 1184\u20131187. https:\/\/doi.org\/10.1016\/j.ejca.2008.11.046 (2009).","journal-title":"Eur. J. Cancer"},{"key":"62057_CR18","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1007\/s00520-014-2182-7","volume":"22","author":"S Hamada","year":"2014","unstructured":"Hamada, S. et al. Antiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy. Support Care Cancer 22, 2161\u20132166. https:\/\/doi.org\/10.1007\/s00520-014-2182-7 (2014).","journal-title":"Support Care Cancer"},{"key":"62057_CR19","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1093\/annonc\/mdu096","volume":"25","author":"RJ Gralla","year":"2014","unstructured":"Gralla, R. J. et al. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann. Oncol. 25, 1333\u20131339. https:\/\/doi.org\/10.1093\/annonc\/mdu096 (2014).","journal-title":"Ann. Oncol."},{"key":"62057_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejphar.2012.05.037","volume":"689","author":"M Stathis","year":"2012","unstructured":"Stathis, M., Pietra, C., Rojas, C. & Slusher, B. S. Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects. Eur. J. Pharmacol. 689, 25\u201330. https:\/\/doi.org\/10.1016\/j.ejphar.2012.05.037 (2012).","journal-title":"Eur. J. Pharmacol."},{"key":"62057_CR21","doi-asserted-by":"publisher","first-page":"806","DOI":"10.2174\/1568009622666220513094352","volume":"22","author":"M Aapro","year":"2022","unstructured":"Aapro, M. et al. Netupitant-palonosetron (NEPA) for preventing chemotherapy-induced nausea and vomiting: From clinical trials to daily practice. Curr. Cancer Drug Targ. 22, 806\u2013824. https:\/\/doi.org\/10.2174\/1568009622666220513094352 (2022).","journal-title":"Curr. Cancer Drug Targ."},{"key":"62057_CR22","doi-asserted-by":"publisher","first-page":"939","DOI":"10.2217\/fon-2020-0187","volume":"16","author":"M Karthaus","year":"2020","unstructured":"Karthaus, M. et al. Real-world evidence of NEPA, netupitant-palonosetron, in chemotherapy-induced nausea and vomiting prevention: Effects on quality of life. Future Oncol. 16, 939\u2013953. https:\/\/doi.org\/10.2217\/fon-2020-0187 (2020).","journal-title":"Future Oncol."},{"key":"62057_CR23","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1093\/annonc\/mdu101","volume":"25","author":"M Aapro","year":"2014","unstructured":"Aapro, M. et al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann. Oncol. 25, 1328\u20131333. https:\/\/doi.org\/10.1093\/annonc\/mdu101 (2014).","journal-title":"Ann. Oncol."},{"key":"62057_CR24","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3109\/10428194.2013.813498","volume":"55","author":"BS Choi","year":"2014","unstructured":"Choi, B. S., Borsaru, G. P., Ballinari, G., Voisin, D. & Di Renzo, N. Multicenter phase IV study of palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with non-hodgkin lymphomas undergoing repeated cycles of moderately emetogenic chemotherapy. Leuk. Lymphoma 55, 544\u2013550. https:\/\/doi.org\/10.3109\/10428194.2013.813498 (2014).","journal-title":"Leuk. Lymphoma"},{"key":"62057_CR25","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1007\/s12185-016-2089-9","volume":"104","author":"Y Miyata","year":"2016","unstructured":"Miyata, Y. et al. A prospective study of the antiemetic effect of palonosetron in malignant lymphoma patients treated with the CHOP regimen. Int. J. Hematol. 104, 682\u2013691. https:\/\/doi.org\/10.1007\/s12185-016-2089-9 (2016).","journal-title":"Int. J. Hematol."},{"key":"62057_CR26","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s12185-016-2041-z","volume":"104","author":"T Takahashi","year":"2016","unstructured":"Takahashi, T. et al. A retrospective study of R\u2013CHOP\/CHOP therapy-induced nausea and vomiting in non-Hodgkin\u2019s lymphoma patients: A comparison of intravenous and oral 5-HT3 receptor antagonists. Int. J. Hematol. 104, 378\u2013383. https:\/\/doi.org\/10.1007\/s12185-016-2041-z (2016).","journal-title":"Int. J. Hematol."},{"key":"62057_CR27","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40780-019-0153-3","volume":"5","author":"Y Wakasugi","year":"2019","unstructured":"Wakasugi, Y. et al. Granisetron plus aprepitant versus granisetron in preventing nausea and vomiting during CHOP or R\u2013CHOP regimen in malignant lymphoma: A retrospective study. J. Pharm. Health Care Sci. 5, 24. https:\/\/doi.org\/10.1186\/s40780-019-0153-3 (2019).","journal-title":"J. Pharm. Health Care Sci."},{"key":"62057_CR28","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1093\/annonc\/mdx698","volume":"29","author":"L Zhang","year":"2018","unstructured":"Zhang, L. et al. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Ann. Oncol. 29, 452\u2013458. https:\/\/doi.org\/10.1093\/annonc\/mdx698 (2018).","journal-title":"Ann. Oncol."},{"key":"62057_CR29","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/annonc\/mdl347","volume":"18","author":"SM Grunberg","year":"2007","unstructured":"Grunberg, S. M. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: Dosing, efficacy, and tolerability analysis. Ann. Oncol. 18, 233\u2013240. https:\/\/doi.org\/10.1093\/annonc\/mdl347 (2007).","journal-title":"Ann. Oncol."},{"key":"62057_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s005209900090","volume":"8","author":"AA Fauser","year":"2000","unstructured":"Fauser, A. A., Pizzocaro, G., Schueller, J., Khayat, D. & Wilkinson, P. A double-blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatin-related nausea and vomiting. Support Care Cancer 8, 49\u201354. https:\/\/doi.org\/10.1007\/s005209900090 (2000).","journal-title":"Support Care Cancer"},{"key":"62057_CR31","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s00520-003-0528-7","volume":"12","author":"A Villalon","year":"2004","unstructured":"Villalon, A. & Chan, V. Multicenter, randomized trial of ramosetron plus dexamethasone versus ramosetron alone in controlling cisplatin-induced emesis. Support Care Cancer 12, 58\u201363. https:\/\/doi.org\/10.1007\/s00520-003-0528-7 (2004).","journal-title":"Support Care Cancer"},{"key":"62057_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/nejm199501053320101","volume":"332","author":"Italian Group for Antiemetic Research","year":"1995","unstructured":"Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N. Engl. J. Med. 332, 1\u20135. https:\/\/doi.org\/10.1056\/nejm199501053320101 (1995).","journal-title":"N. Engl. J. Med."},{"key":"62057_CR33","doi-asserted-by":"publisher","first-page":"e524","DOI":"10.1093\/oncolo\/oyac060","volume":"27","author":"D Watanabe","year":"2022","unstructured":"Watanabe, D. et al. One-day versus three-day dexamethasone with nk1ra for patients receiving carboplatin and moderate emetogenic chemotherapy: A network meta-analysis. Oncologist 27, e524\u2013e532. https:\/\/doi.org\/10.1093\/oncolo\/oyac060 (2022).","journal-title":"Oncologist"},{"key":"62057_CR34","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41416-023-02493-7","volume":"130","author":"H Minatogawa","year":"2024","unstructured":"Minatogawa, H. et al. Dexamethasone-sparing on days 2\u20134 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial). Br. J. Cancer 130, 224\u2013232. https:\/\/doi.org\/10.1038\/s41416-023-02493-7 (2024).","journal-title":"Br. J. Cancer"},{"key":"62057_CR35","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.1136\/bmjspcare-2019-002037","volume":"12","author":"W Yeo","year":"2022","unstructured":"Yeo, W. et al. NEPA efficacy and tolerability during (neo)adjuvant breast cancer chemotherapy with cyclophosphamide and doxorubicin. BMJ Support Palliat. Care 12, e264\u2013e270. https:\/\/doi.org\/10.1136\/bmjspcare-2019-002037 (2022).","journal-title":"BMJ Support Palliat. Care"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-62057-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-62057-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-62057-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T14:10:38Z","timestamp":1715868638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-62057-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["62057"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-62057-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2024,5,16]]},"assertion":[{"value":"2 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11229"}}